Table 5.
Comparison of TMPG between groups before and after treatment
| Variable | Preoperative | Immediate postoperative period | 6-month postoperative | |||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| Level 0-2 | Level 3 | Level 0-2 | Level 3 | Level 0-2 | Level 3 | |
| Control group (n=55) | 49 (89.1) | 6 (10.9) | 9 (16.4) | 46 (83.6) | 6 (10.9) | 49 (89.1) |
| PCSK9 inhibitor group (n=55) | 50 (90.9) | 5 (9.1) | 8 (14.5) | 47 (85.5) | 1 (1.8) | 54 (98.2) |
| χ2 | 0.101 | 0.07 | 4.131 | |||
| P | 0.751 | 0.791 | 0.04 | |||
Note: All data are presented as n (%). Abbreviations: PCSK9, proprotein convertase subtilisin/kexin 9; TMPG, Thrombosis in Myocardial Infarction (TIMI) Myocardial Perfusion Grade.